Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium. The symposium will include a seminar on immuno-oncology on Wednesday, September 28, 2022, at which Dr. Conejo-Garcia is an invited lecturer.
During the presentation, Dr. Conejo-Garcia will discuss the CAR-T technology, which is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, and the target-binding domain is derived from its natural ligand, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology.
“I am excited to discuss our novel FSHR-mediated CAR-T technology at this seminar series and to share ideas and advance the field of ovarian cancer research,” stated Dr. Conejo-Garcia. “Moffitt and Anixa have been working together to advance this ovarian cancer therapy and we are thrilled to have treated the first patient in our ongoing clinical trial. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer.”
More information about the event may be found at: https://rivkin.org/symposia/ocrs/.
